Christopher Yuskaitis, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 15 | 2024 | 298 | 3.360 |
Why?
|
| GTPase-Activating Proteins | 4 | 2022 | 471 | 1.790 |
Why?
|
| Glycogen Synthase Kinase 3 | 6 | 2010 | 411 | 0.850 |
Why?
|
| Seizures | 8 | 2024 | 2957 | 0.780 |
Why?
|
| Pentylenetetrazole | 1 | 2021 | 71 | 0.760 |
Why?
|
| Convulsants | 1 | 2021 | 70 | 0.760 |
Why?
|
| Epilepsy | 9 | 2023 | 3290 | 0.720 |
Why?
|
| Fragile X Syndrome | 3 | 2010 | 116 | 0.710 |
Why?
|
| Social Isolation | 1 | 2021 | 364 | 0.610 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2013 | 116 | 0.600 |
Why?
|
| Fasting | 1 | 2022 | 1602 | 0.530 |
Why?
|
| Malformations of Cortical Development | 1 | 2017 | 176 | 0.510 |
Why?
|
| Epilepsies, Partial | 1 | 2017 | 431 | 0.450 |
Why?
|
| Dyslexia | 1 | 2015 | 208 | 0.450 |
Why?
|
| Anticonvulsants | 7 | 2022 | 1906 | 0.450 |
Why?
|
| Neurons | 4 | 2022 | 9462 | 0.420 |
Why?
|
| Vigabatrin | 3 | 2022 | 88 | 0.420 |
Why?
|
| Spasm | 5 | 2024 | 130 | 0.400 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2022 | 618 | 0.380 |
Why?
|
| Electroencephalography | 9 | 2024 | 6224 | 0.370 |
Why?
|
| Lithium Chloride | 2 | 2010 | 82 | 0.360 |
Why?
|
| Developmental Disabilities | 2 | 2018 | 1509 | 0.340 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2734 | 0.340 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2022 | 2057 | 0.340 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 18247 | 0.320 |
Why?
|
| Avoidance Learning | 1 | 2010 | 248 | 0.300 |
Why?
|
| Astrocytes | 2 | 2017 | 1345 | 0.290 |
Why?
|
| Mice, Knockout | 8 | 2022 | 14409 | 0.270 |
Why?
|
| Child Development | 1 | 2018 | 2305 | 0.270 |
Why?
|
| Immune System | 1 | 2010 | 795 | 0.240 |
Why?
|
| Microglia | 2 | 2010 | 1361 | 0.220 |
Why?
|
| Prednisolone | 2 | 2021 | 326 | 0.210 |
Why?
|
| Infant | 15 | 2024 | 36205 | 0.200 |
Why?
|
| Mice, Inbred CBA | 1 | 2021 | 436 | 0.180 |
Why?
|
| Mice, 129 Strain | 1 | 2021 | 371 | 0.180 |
Why?
|
| Adaptor Protein Complex 4 | 1 | 2020 | 40 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 2803 | 0.170 |
Why?
|
| Lissencephaly | 1 | 2020 | 36 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 1886 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 112 | 0.160 |
Why?
|
| Genes, Lethal | 1 | 2019 | 225 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 17912 | 0.160 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2020 | 168 | 0.150 |
Why?
|
| Brain | 7 | 2022 | 27107 | 0.150 |
Why?
|
| Sequence Analysis | 1 | 2018 | 240 | 0.150 |
Why?
|
| Mice | 10 | 2022 | 81509 | 0.140 |
Why?
|
| Congenital Abnormalities | 1 | 2022 | 709 | 0.140 |
Why?
|
| Tuberous Sclerosis | 2 | 2022 | 1030 | 0.140 |
Why?
|
| Species Specificity | 1 | 2021 | 2416 | 0.140 |
Why?
|
| Gliosis | 1 | 2017 | 244 | 0.140 |
Why?
|
| Hormones | 1 | 2021 | 869 | 0.140 |
Why?
|
| Barbiturates | 1 | 2017 | 113 | 0.140 |
Why?
|
| Standard of Care | 1 | 2020 | 550 | 0.130 |
Why?
|
| Animals | 13 | 2022 | 168441 | 0.130 |
Why?
|
| Carbamazepine | 1 | 2017 | 224 | 0.130 |
Why?
|
| Amino Acids | 1 | 2022 | 1718 | 0.130 |
Why?
|
| Neocortex | 1 | 2020 | 417 | 0.130 |
Why?
|
| Age of Onset | 2 | 2024 | 3304 | 0.130 |
Why?
|
| Corpus Callosum | 1 | 2020 | 751 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2022 | 6581 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 2469 | 0.120 |
Why?
|
| Pitch Perception | 1 | 2015 | 101 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 1342 | 0.120 |
Why?
|
| Cell Movement | 3 | 2020 | 5203 | 0.110 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2013 | 13 | 0.110 |
Why?
|
| Retrospective Studies | 12 | 2024 | 80582 | 0.110 |
Why?
|
| Outpatients | 1 | 2021 | 1597 | 0.110 |
Why?
|
| Coma | 1 | 2017 | 484 | 0.110 |
Why?
|
| Syndrome | 3 | 2024 | 3268 | 0.110 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2013 | 158 | 0.100 |
Why?
|
| Music | 1 | 2015 | 245 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3082 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3202 | 0.100 |
Why?
|
| Sirolimus | 1 | 2019 | 1533 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 22163 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 2871 | 0.100 |
Why?
|
| Cognition | 2 | 2022 | 6986 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 1606 | 0.100 |
Why?
|
| Child | 10 | 2023 | 80162 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2161 | 0.090 |
Why?
|
| Phenotype | 2 | 2019 | 16606 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2019 | 901 | 0.090 |
Why?
|
| Speech | 1 | 2015 | 554 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8641 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 36423 | 0.090 |
Why?
|
| Comprehension | 1 | 2015 | 621 | 0.090 |
Why?
|
| Male | 19 | 2023 | 360736 | 0.090 |
Why?
|
| Humans | 29 | 2024 | 761423 | 0.080 |
Why?
|
| Lithium Carbonate | 1 | 2010 | 179 | 0.080 |
Why?
|
| Serine | 2 | 2010 | 830 | 0.080 |
Why?
|
| Genome, Human | 1 | 2022 | 4425 | 0.080 |
Why?
|
| Child, Preschool | 7 | 2020 | 42254 | 0.080 |
Why?
|
| Lithium | 2 | 2010 | 596 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2023 | 3269 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 552 | 0.080 |
Why?
|
| Hippocampus | 1 | 2021 | 3763 | 0.080 |
Why?
|
| Female | 17 | 2023 | 392581 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2018 | 2985 | 0.070 |
Why?
|
| Sex Factors | 1 | 2021 | 10548 | 0.070 |
Why?
|
| Oximes | 1 | 2008 | 303 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2019 | 23441 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2010 | 1647 | 0.070 |
Why?
|
| Testis | 1 | 2010 | 794 | 0.070 |
Why?
|
| Benzazepines | 1 | 2008 | 310 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 908 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8529 | 0.060 |
Why?
|
| Genotype | 1 | 2019 | 13009 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18400 | 0.060 |
Why?
|
| Indoles | 2 | 2008 | 1832 | 0.060 |
Why?
|
| Munc18 Proteins | 1 | 2022 | 20 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 64651 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 2207 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2023 | 41446 | 0.040 |
Why?
|
| Autistic Disorder | 1 | 2010 | 1220 | 0.040 |
Why?
|
| Centrioles | 1 | 2020 | 80 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2008 | 2133 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2010 | 8320 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2022 | 3538 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3207 | 0.040 |
Why?
|
| Pedigree | 2 | 2018 | 4589 | 0.040 |
Why?
|
| Mutation | 3 | 2022 | 30045 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 898 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2020 | 203 | 0.040 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 18 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 266 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 29620 | 0.040 |
Why?
|
| Brugada Syndrome | 1 | 2018 | 93 | 0.040 |
Why?
|
| Decontamination | 1 | 2017 | 72 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 1808 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2017 | 206 | 0.030 |
Why?
|
| Cytokines | 1 | 2010 | 7392 | 0.030 |
Why?
|
| Anxiety | 1 | 2010 | 4572 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1571 | 0.030 |
Why?
|
| Microtubules | 1 | 2020 | 1074 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 935 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10766 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2455 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2020 | 26212 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2863 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2008 | 18964 | 0.030 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2013 | 167 | 0.030 |
Why?
|
| Neurology | 1 | 2020 | 780 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2018 | 1118 | 0.020 |
Why?
|
| Consanguinity | 1 | 2013 | 456 | 0.020 |
Why?
|
| Adolescent | 4 | 2022 | 88313 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 1998 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 11902 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26112 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2020 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2507 | 0.020 |
Why?
|
| Receptors, GABA-A | 1 | 2013 | 623 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7219 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 150 | 0.020 |
Why?
|
| Citrates | 1 | 2008 | 135 | 0.020 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 600 | 0.020 |
Why?
|
| Maleimides | 1 | 2008 | 113 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2022 | 4391 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2013 | 2382 | 0.020 |
Why?
|
| Probability | 1 | 2013 | 2478 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5492 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2017 | 1797 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 279 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 4414 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39117 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 10762 | 0.020 |
Why?
|
| Urea | 1 | 2008 | 444 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2008 | 448 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9330 | 0.020 |
Why?
|
| Antimanic Agents | 1 | 2008 | 520 | 0.010 |
Why?
|
| Registries | 1 | 2020 | 8223 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 2008 | 1235 | 0.010 |
Why?
|
| Choice Behavior | 1 | 2010 | 824 | 0.010 |
Why?
|
| Young Adult | 2 | 2020 | 59207 | 0.010 |
Why?
|
| Social Behavior | 1 | 2010 | 1134 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7389 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 3051 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5335 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2010 | 1878 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 1171 | 0.010 |
Why?
|
| Mental Disorders | 2 | 2015 | 6841 | 0.010 |
Why?
|
| Thiazoles | 1 | 2008 | 1517 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6231 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2023 | 54415 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3712 | 0.010 |
Why?
|
| Pyridines | 1 | 2008 | 2875 | 0.010 |
Why?
|
| United States | 1 | 2023 | 72339 | 0.010 |
Why?
|
| Adult | 2 | 2020 | 221148 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 74167 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 5840 | 0.000 |
Why?
|
| Middle Aged | 1 | 2020 | 220826 | 0.000 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 8596 | 0.000 |
Why?
|
| Neoplasms | 1 | 2006 | 22164 | 0.000 |
Why?
|